Pharma R&D Today

Ideas and Insight supporting all stages of Drug Discovery & Development

Select category
Search this blog
Christy J. Wilson

Christy J. Wilson

Sr. Director, Pharma and Biotech Segment

Connect with Christy J. Wilson on LinkedIn
Follow Christy J. Wilson on Twitter
Website:

About the author: Christy brings more than 20 years of global life science and healthcare industry experience to her role as Senior Director, Segment Marketing for the biopharmaceutical industry segment at Elsevier. In this capacity she is focused on understanding biopharmaceutical R&D challenges and the implications for Elsevier in terms of market led growth opportunities that will improve productivity and success for industry executives and their teams. She also plays a key role in increasing Elsevier’s share-of-voice and market share through strategic go-to-market planning and execution. Prior to joining Elsevier, Christy held senior marketing and business development roles in Wolters Kluwer’s Pharma Solutions Business Unit where she was responsible for product management and marketing of the Adis portfolio of drug focused journals and newsletters, pipeline and clinical trials intelligence tools, and pharmacovigilance solutions. During her Wolters Kluwer tenure, Christy also worked in the group’s Healthcare Analytics business, a business that provided powerful data, applications, analytics, and consulting to help companies gain deep insight into the pharmaceutical market. Christy resides in the greater New York City area and holds an MBA in International Business from DePaul University (Chicago) and a BS in Marketing, from Miami University (Ohio).

Posts by Christy J. Wilson

Is Bacteria in the Gut Compromising the Efficacy and Safety of the Drugs We Take?

Posted on July 2nd, 2019 in Pharma R&D

Even the most reliable drugs don’t work exactly the same for everyone who takes them. The reason for this is an ongoing mystery, but a new study just published in Nature suggests that it may have a lot to do with the microbiome.

(more…)

How Can the Life Sciences Benefit from Using Simulated Data?

Posted on June 28th, 2019 in Pharma R&D

The life sciences, like many sectors, are putting a higher and higher premium on good data. In our digital world, access to reliable data is a necessity, whether it’s healthcare providers counting on data analytics to inform patient care or drug developers requiring insightful data to create effective new therapies.

(more…)

Medicare May Join Forces with Apple Watch to Monitor Consumer Health

Posted on May 1st, 2019 in Pharma R&D

Istanbul, Turkey – September 6, 2015: A woman wearing 42mm stainless steel Apple Watch with white sports band. The Apple Watch became available April 24, 2015, bringing a new way to receive information at a glance, using apps designed specifically for the wrist.

Apple is a company that has long been thought of us an innovator that has brought consumers an array of enticing gadgets, from home computers to iPods to smartphones. This technology has been transformative for its users, but mostly it has been associated with work and play. Increasingly, though, Apple appears to be interested in getting involved in another critical part of our lives: our health.

(more…)

Three factors to unlock the value of AI for life sciences

Posted on May 1st, 2019 in Pharma R&D

Artificial Intelligence (AI) has been at the top of many boardroom agendas for the last several years, as execs try to integrate the technology. Recent RELX research found that, across all industries, 88 percent of senior executives believe AI will help their businesses be more competitive. In the life sciences, AI has the potential to scale the benefits of precision medicine or automated disease prediction to more patients across the world, and could generate more than $150 billion in savings for the healthcare industry by 2025. 

3d rendering robot hand working with security laptop
(more…)

  1. 1
  2. 2
  3. 3
  4. 12